Revvity, Inc. (NYSE:RVTY) Shares Sold by Guardian Wealth Management Inc.

Guardian Wealth Management Inc. decreased its stake in Revvity, Inc. (NYSE:RVTY) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,702 shares of the company’s stock after selling 2,094 shares during the period. Guardian Wealth Management Inc.’s holdings in Revvity were worth $1,083,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Assetmark Inc. boosted its holdings in Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after purchasing an additional 259 shares during the last quarter. Millstone Evans Group LLC bought a new stake in shares of Revvity in the 4th quarter worth about $38,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after purchasing an additional 138 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Revvity by 33.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock worth $58,000 after purchasing an additional 131 shares in the last quarter. Finally, GeoWealth Management LLC bought a new stake in Revvity in the fourth quarter valued at about $60,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Price Performance

Shares of NYSE RVTY opened at $93.73 on Thursday. The firm has a 50-day moving average of $105.56 and a two-hundred day moving average of $113.47. The company has a market capitalization of $11.26 billion, a price-to-earnings ratio of 42.41, a PEG ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a twelve month low of $88.53 and a twelve month high of $129.50.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm posted $1.25 earnings per share. As a group, analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares of the company’s stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.68% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. KeyCorp lifted their target price on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Barclays dropped their target price on shares of Revvity from $140.00 to $110.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Wells Fargo & Company cut their target price on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Sanford C. Bernstein cut Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target on the stock. in a research report on Friday, January 10th. Finally, Robert W. Baird reduced their price objective on Revvity from $141.00 to $127.00 and set an “outperform” rating for the company in a research report on Monday. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.50.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.